Coherus Oncology (CHRS) Revenue Growth (1y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 64.24% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 7.82% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 19.04% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3,790.58% |
| 10 | Coherus Oncology | 216.87 Mn | 49.83 Mn | 8.50 Mn | 61.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61.99% |
| Dec 31, 2025 | 64.85% |
| Sep 30, 2025 | 91.19% |
| Jun 30, 2025 | -0.41% |
| Mar 31, 2025 | 229.25% |
| Dec 31, 2024 | -91.55% |
| Sep 30, 2024 | -91.88% |
| Jun 30, 2024 | -82.46% |
| Mar 31, 2024 | -92.88% |
| Dec 31, 2023 | 101.81% |
| Sep 30, 2023 | 64.16% |
| Jun 30, 2023 | -2.39% |
| Mar 31, 2023 | -46.04% |
| Dec 31, 2022 | -38.19% |
| Sep 30, 2022 | -44.94% |
| Jun 30, 2022 | -31.33% |
| Mar 31, 2022 | -27.60% |
| Dec 31, 2021 | -33.55% |
| Sep 30, 2021 | -27.34% |
| Jun 30, 2021 | -35.43% |
| Mar 31, 2021 | -28.53% |
| Dec 31, 2020 | -10.86% |
| Sep 30, 2020 | 1.66% |
| Jun 30, 2020 | 62.68% |
| Mar 31, 2020 | 213.17% |
| Jun 30, 2017 | -90.05% |
| Mar 31, 2017 | -98.70% |
| Dec 31, 2016 | -91.72% |
| Sep 30, 2016 | 2,172.01% |
| Jun 30, 2016 | 104.89% |
| Mar 31, 2016 | 112.72% |
| Dec 31, 2015 | 57.06% |
| Sep 30, 2015 | -55.35% |
| Jun 30, 2015 | 38.29% |
| Mar 31, 2015 | 61.57% |
| Dec 31, 2014 | 427.03% |
| Sep 30, 2014 | 3,072.33% |